January 2026 Research Update

This month added a clearer picture that focal congenital hyperinsulinism (CHI) is being treated with increasingly targeted surgery, and that newer surgical approaches may perform similarly to open surgery in small comparisons. In one center, robotic surgery and open surgery had broadly similar recovery measures, and most children in both groups were reported to be cured, though a few needed a second procedure after an incomplete first resection. A separate single-patient report also described imaging-guided focal surgery that preserved most of the pancreas and stopped hypoglycemia, showing how precise localization can support limited resection. [1] [2]

In the retrospective comparison (20 children total), the robotic group had a reported cure rate of 90% and the open group 80%, with no intraoperative bleeding or conversions reported in either group. Two incomplete resections happened in each group, and the robotic cases with incomplete resection underwent a second procedure after multidisciplinary review. Because this was a small, single-center look back at prior care, it cannot prove one approach is better, but it helps describe what outcomes looked like in routine practice at that site. [1]

The case report connected surgery decisions to real-world complications and timing. A newborn with diazoxide-unresponsive CHI developed necrotizing enterocolitis (a severe bowel injury) shortly after a very low dose of octreotide, and then had focal lesion surgery guided by 18F-DOPA PET/CT; hypoglycemia resolved after resection that spared most normal pancreas. As a single case, it cannot show how often this happens, but it illustrates the kind of high-stakes decisions that can surround bridging treatments and the value of accurate lesion localization when surgery is planned. [2]

For families dealing with focal CHI, this month mainly adds practical context about how focal lesions are surgically managed rather than introducing a new medicine. The robotic versus open comparison suggests that, in one center, robotic focal pancreatectomy was feasible with similar short-term recovery measures to open surgery, but the evidence is still early because the numbers were small and not randomized. The single-patient report highlights that severe complications can occur around treatments used when CHI is hard to control, but it does not establish risk levels; it also reinforces that imaging-guided focal surgery can be used to remove a limited area and resolve hypoglycemia in at least some situations. [1] [2]

Across studies this month, the consistent message was that combining genetics with specialized PET imaging is central to identifying focal CHI and planning targeted surgery. One paper emphasized 18F-FDOPA PET imaging for locating focal lesions and described rapid genetic analysis as a way to select which children are most likely to benefit from that scan. A separate small clinical series showed that targeted genetic testing can find likely disease-causing variants in some children, while others remain without an identified genetic answer. [3] [4]

The imaging-focused report described the role of 18F-FDOPA PET in localizing focal lesions and stated that rapid genetic analysis helps predict the likelihood of focal disease and guide who should receive the scan. It also noted that around half of children may have a focal form that can be cured by resection, which is why the localization step matters so much in the overall care pathway. Details like study size and specific performance measures were not provided in the summary, so the report functions more as an evaluation and overview than as a head-to-head accuracy study. [3]

In a six-infant single-center series using a 19-gene CHI panel with Sanger sequencing, likely pathogenic variants were identified in 3 of 6 patients, including ABCC8 in two and KCNJ11 in one. Diazoxide response varied (two responsive and four unresponsive), and two unresponsive cases underwent partial pancreatectomy. The study underlines both the usefulness and the current limits of genetic testing, since half of the children did not have a likely genetic cause identified with this approach. [4]

This theme matters because identifying focal versus diffuse CHI can shape the testing and surgical planning families may encounter, but this month did not provide new accuracy numbers or new diagnostic rules. The studies add reassurance that genetics and 18F-FDOPA PET are being used together as a coordinated approach to localization and decision-making, and they illustrate why speed in genetic results may be important when deciding whether a specialized scan is likely to help. Uncertainty remains because the genetic-testing series was very small and used a limited testing method, and the imaging paper summary did not include detailed performance outcomes, so the month mainly adds understanding rather than changing what is known to work. [3] [4]

This month strengthened the idea that CHI is not always a single, uniform pancreas problem, and that some children may have mixed or atypical tissue patterns tied to specific genetic changes. Tissue-based studies reported signs that some insulin-making cells look less like typical mature beta cells, and that rare genetic changes may only be detectable when DNA is tested directly from isolated islets. Together, these studies focus on explaining why CHI can behave differently across children, rather than testing a treatment. [5] [6]

In pancreatic tissue from 11 children who had surgery (5 focal CHI and 6 diffuse CHI), researchers measured cell types using markers for insulin, glucagon, and PDX1 (a beta-cell maturity marker). Diffuse CHI tissue showed a higher proportion of insulin-positive cells that lacked PDX1 and more bi-hormonal insulin-plus-glucagon cells, which the authors interpreted as possible beta-cell dedifferentiation or a shift toward mixed cell identity under CHI conditions. Focal CHI tissue showed similar trends, but differences were not always statistically clear when compared with tissue outside the focal lesion. [5]

A separate surgical series described 5 children with what the authors called histologically atypical CHI, identified among 70 surgically treated patients. In 3 of these 5, variants in HK1 intron 2 were found in heterozygous or low-grade mosaic form, and in one child a CACNA1D frameshift variant was reported; one child had no detected variant. An important practical point from this study was that very low-level mosaic changes could be missed in blood or whole-tissue testing and only detected when islets were isolated with laser-capture microdissection. [6]

For patients and caregivers, these tissue studies mainly add biological explanation for why CHI can look different from child to child, including differences that might not be captured by routine blood genetic testing. The findings may matter more in the future, because they point to cell-level changes and mosaic genetic variants that could eventually refine how CHI is classified or studied. Right now, the evidence is exploratory and based on small numbers of surgical samples, so it helps clarify possible mechanisms and testing challenges rather than providing immediate changes to treatment choices. [5] [6]

This month included case reports showing that high-insulin hypoglycemia can arise in different medical contexts, and that the details of timing and triggers can matter. One report was true congenital hyperinsulinism with imaging-guided focal surgery, while another described high-insulin hypoglycemia in congenital central hypoventilation syndrome (CCHS) that was presented as reactive and linked to autonomic dysregulation rather than CHI. Together, they reinforce that similar low-glucose events can have different underlying causes, even when insulin levels are high. [2] [7]

In the CCHS case, a 4-month-old girl with a PHOX2B polyalanine expansion had recurrent low blood sugar after meals, with high insulin and C-peptide and suppressed ketones during hypoglycemia. The authors interpreted this as reactive postprandial hyperinsulinemic hypoglycemia related to autonomic dysregulation, rather than congenital hyperinsulinism. Glucose stability was reported with slow continuous feeding, while rapid dextrose boluses were reported to trigger rebound hypoglycemia. [7]

Case reports do not predict what will happen for most families, but they can clarify what is possible and what clinicians may consider when a situation does not fit the usual pattern. This month, the reports highlight that high-insulin hypoglycemia is not always caused by CHI, and that another condition (CCHS) can produce a similar lab picture with different reasoning about the cause. They also add early safety context by describing a severe bowel complication after very low-dose octreotide in one newborn with CHI, but a single case cannot estimate risk; the main value is awareness that individual responses and complications can be unpredictable. [2] [7]